Efficacy of fecal microbiota transplantation in patients with Parkinson’s disease: clinical trial results from a randomized, placebo-controlled design
ABSTRACTThe occurrence and development of Parkinson’s disease (PD) have been demonstrated to be related to gut dysbiosis, however, the impact of fecal microbiota transplantation (FMT) on microbiota engraftment in PD patients is uncertain. We performed a randomized, placebo-controlled trial at the De...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Gut Microbes |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2023.2284247 |
| _version_ | 1797320567418781696 |
|---|---|
| author | Yi Cheng Guohua Tan Qihui Zhu Chun Wang Guangcong Ruan Senhong Ying Jinlong Qie Xiaofei Hu Zhifeng Xiao Fenghua Xu Lu Chen Minjia Chen Yang Pei Hao Zhang Yuting Tian Dongfeng Chen Xingyin Liu Heqing Huang Yanling Wei |
| author_facet | Yi Cheng Guohua Tan Qihui Zhu Chun Wang Guangcong Ruan Senhong Ying Jinlong Qie Xiaofei Hu Zhifeng Xiao Fenghua Xu Lu Chen Minjia Chen Yang Pei Hao Zhang Yuting Tian Dongfeng Chen Xingyin Liu Heqing Huang Yanling Wei |
| author_sort | Yi Cheng |
| collection | DOAJ |
| description | ABSTRACTThe occurrence and development of Parkinson’s disease (PD) have been demonstrated to be related to gut dysbiosis, however, the impact of fecal microbiota transplantation (FMT) on microbiota engraftment in PD patients is uncertain. We performed a randomized, placebo-controlled trial at the Department of Neurology, Army Medical University Southwest Hospital in China (ChiCTR1900021405) from February 2019 to December 2019. Fifty-six participants with mild to moderate PD (Hoehn-Yahr stage 1–3) were randomly assigned to the FMT and placebo group, 27 patients in the FMT group and 27 in the placebo group completed the whole trial. During the follow-up, no severe adverse effect was observed, and patients with FMT treatment showed significant improvement in PD-related autonomic symptoms compared with the placebo group at the end of this trial (MDS-UPDRS total score, group×time effect, B = -6.56 [−12.98, −0.13], P < 0.05). Additionally, FMT improved gastrointestinal disorders and a marked increase in the complexity of the microecological system in patients. This study demonstrated that FMT through oral administration is clinically feasible and has the potential to improve the effectiveness of current medications in the clinical symptoms of PD patients. |
| first_indexed | 2024-03-08T04:41:02Z |
| format | Article |
| id | doaj.art-8e1e91d0cc2640c5b5bc9d87023a275d |
| institution | Directory Open Access Journal |
| issn | 1949-0976 1949-0984 |
| language | English |
| last_indexed | 2024-03-08T04:41:02Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Gut Microbes |
| spelling | doaj.art-8e1e91d0cc2640c5b5bc9d87023a275d2024-02-08T12:02:08ZengTaylor & Francis GroupGut Microbes1949-09761949-09842023-12-0115210.1080/19490976.2023.2284247Efficacy of fecal microbiota transplantation in patients with Parkinson’s disease: clinical trial results from a randomized, placebo-controlled designYi Cheng0Guohua Tan1Qihui Zhu2Chun Wang3Guangcong Ruan4Senhong Ying5Jinlong Qie6Xiaofei Hu7Zhifeng Xiao8Fenghua Xu9Lu Chen10Minjia Chen11Yang Pei12Hao Zhang13Yuting Tian14Dongfeng Chen15Xingyin Liu16Heqing Huang17Yanling Wei18Department of Gastroenterology, Chongqing Key Laboratory of Digestive Malignancies, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Neurology, Southwest Hospital, Army Medical University, Chongqing, ChinaDepartment of Pathogen Biology-Microbiology Division, Key Laboratory of Pathogen of Jiangsu Province; The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital Gusu School, Nanjing Medical University, Jiangsu, ChinaDepartment of Gastroenterology, Chongqing Key Laboratory of Digestive Malignancies, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Gastroenterology, Chongqing Key Laboratory of Digestive Malignancies, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Gastroenterology, Chongqing Key Laboratory of Digestive Malignancies, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Pathogen Biology-Microbiology Division, Key Laboratory of Pathogen of Jiangsu Province; The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital Gusu School, Nanjing Medical University, Jiangsu, ChinaDepartment of Radiology, Southwest Hospital, Army Medical University, Chongqing, ChinaDepartment of Gastroenterology, Chongqing Key Laboratory of Digestive Malignancies, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Gastroenterology, Chongqing Key Laboratory of Digestive Malignancies, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Gastroenterology, Chongqing Key Laboratory of Digestive Malignancies, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Gastroenterology, Chongqing Key Laboratory of Digestive Malignancies, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Pathogen Biology-Microbiology Division, Key Laboratory of Pathogen of Jiangsu Province; The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital Gusu School, Nanjing Medical University, Jiangsu, ChinaDepartment of Gastroenterology, Chongqing Key Laboratory of Digestive Malignancies, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Gastroenterology, Chongqing Key Laboratory of Digestive Malignancies, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Gastroenterology, Chongqing Key Laboratory of Digestive Malignancies, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Pathogen Biology-Microbiology Division, Key Laboratory of Pathogen of Jiangsu Province; The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital Gusu School, Nanjing Medical University, Jiangsu, ChinaDepartment of Neurology, Southwest Hospital, Army Medical University, Chongqing, ChinaDepartment of Gastroenterology, Chongqing Key Laboratory of Digestive Malignancies, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaABSTRACTThe occurrence and development of Parkinson’s disease (PD) have been demonstrated to be related to gut dysbiosis, however, the impact of fecal microbiota transplantation (FMT) on microbiota engraftment in PD patients is uncertain. We performed a randomized, placebo-controlled trial at the Department of Neurology, Army Medical University Southwest Hospital in China (ChiCTR1900021405) from February 2019 to December 2019. Fifty-six participants with mild to moderate PD (Hoehn-Yahr stage 1–3) were randomly assigned to the FMT and placebo group, 27 patients in the FMT group and 27 in the placebo group completed the whole trial. During the follow-up, no severe adverse effect was observed, and patients with FMT treatment showed significant improvement in PD-related autonomic symptoms compared with the placebo group at the end of this trial (MDS-UPDRS total score, group×time effect, B = -6.56 [−12.98, −0.13], P < 0.05). Additionally, FMT improved gastrointestinal disorders and a marked increase in the complexity of the microecological system in patients. This study demonstrated that FMT through oral administration is clinically feasible and has the potential to improve the effectiveness of current medications in the clinical symptoms of PD patients.https://www.tandfonline.com/doi/10.1080/19490976.2023.2284247Parkinson’s diseaseclinical trialfecal microbiota transplantationgut microbiotamicrobiota-gut-brain axis |
| spellingShingle | Yi Cheng Guohua Tan Qihui Zhu Chun Wang Guangcong Ruan Senhong Ying Jinlong Qie Xiaofei Hu Zhifeng Xiao Fenghua Xu Lu Chen Minjia Chen Yang Pei Hao Zhang Yuting Tian Dongfeng Chen Xingyin Liu Heqing Huang Yanling Wei Efficacy of fecal microbiota transplantation in patients with Parkinson’s disease: clinical trial results from a randomized, placebo-controlled design Gut Microbes Parkinson’s disease clinical trial fecal microbiota transplantation gut microbiota microbiota-gut-brain axis |
| title | Efficacy of fecal microbiota transplantation in patients with Parkinson’s disease: clinical trial results from a randomized, placebo-controlled design |
| title_full | Efficacy of fecal microbiota transplantation in patients with Parkinson’s disease: clinical trial results from a randomized, placebo-controlled design |
| title_fullStr | Efficacy of fecal microbiota transplantation in patients with Parkinson’s disease: clinical trial results from a randomized, placebo-controlled design |
| title_full_unstemmed | Efficacy of fecal microbiota transplantation in patients with Parkinson’s disease: clinical trial results from a randomized, placebo-controlled design |
| title_short | Efficacy of fecal microbiota transplantation in patients with Parkinson’s disease: clinical trial results from a randomized, placebo-controlled design |
| title_sort | efficacy of fecal microbiota transplantation in patients with parkinson s disease clinical trial results from a randomized placebo controlled design |
| topic | Parkinson’s disease clinical trial fecal microbiota transplantation gut microbiota microbiota-gut-brain axis |
| url | https://www.tandfonline.com/doi/10.1080/19490976.2023.2284247 |
| work_keys_str_mv | AT yicheng efficacyoffecalmicrobiotatransplantationinpatientswithparkinsonsdiseaseclinicaltrialresultsfromarandomizedplacebocontrolleddesign AT guohuatan efficacyoffecalmicrobiotatransplantationinpatientswithparkinsonsdiseaseclinicaltrialresultsfromarandomizedplacebocontrolleddesign AT qihuizhu efficacyoffecalmicrobiotatransplantationinpatientswithparkinsonsdiseaseclinicaltrialresultsfromarandomizedplacebocontrolleddesign AT chunwang efficacyoffecalmicrobiotatransplantationinpatientswithparkinsonsdiseaseclinicaltrialresultsfromarandomizedplacebocontrolleddesign AT guangcongruan efficacyoffecalmicrobiotatransplantationinpatientswithparkinsonsdiseaseclinicaltrialresultsfromarandomizedplacebocontrolleddesign AT senhongying efficacyoffecalmicrobiotatransplantationinpatientswithparkinsonsdiseaseclinicaltrialresultsfromarandomizedplacebocontrolleddesign AT jinlongqie efficacyoffecalmicrobiotatransplantationinpatientswithparkinsonsdiseaseclinicaltrialresultsfromarandomizedplacebocontrolleddesign AT xiaofeihu efficacyoffecalmicrobiotatransplantationinpatientswithparkinsonsdiseaseclinicaltrialresultsfromarandomizedplacebocontrolleddesign AT zhifengxiao efficacyoffecalmicrobiotatransplantationinpatientswithparkinsonsdiseaseclinicaltrialresultsfromarandomizedplacebocontrolleddesign AT fenghuaxu efficacyoffecalmicrobiotatransplantationinpatientswithparkinsonsdiseaseclinicaltrialresultsfromarandomizedplacebocontrolleddesign AT luchen efficacyoffecalmicrobiotatransplantationinpatientswithparkinsonsdiseaseclinicaltrialresultsfromarandomizedplacebocontrolleddesign AT minjiachen efficacyoffecalmicrobiotatransplantationinpatientswithparkinsonsdiseaseclinicaltrialresultsfromarandomizedplacebocontrolleddesign AT yangpei efficacyoffecalmicrobiotatransplantationinpatientswithparkinsonsdiseaseclinicaltrialresultsfromarandomizedplacebocontrolleddesign AT haozhang efficacyoffecalmicrobiotatransplantationinpatientswithparkinsonsdiseaseclinicaltrialresultsfromarandomizedplacebocontrolleddesign AT yutingtian efficacyoffecalmicrobiotatransplantationinpatientswithparkinsonsdiseaseclinicaltrialresultsfromarandomizedplacebocontrolleddesign AT dongfengchen efficacyoffecalmicrobiotatransplantationinpatientswithparkinsonsdiseaseclinicaltrialresultsfromarandomizedplacebocontrolleddesign AT xingyinliu efficacyoffecalmicrobiotatransplantationinpatientswithparkinsonsdiseaseclinicaltrialresultsfromarandomizedplacebocontrolleddesign AT heqinghuang efficacyoffecalmicrobiotatransplantationinpatientswithparkinsonsdiseaseclinicaltrialresultsfromarandomizedplacebocontrolleddesign AT yanlingwei efficacyoffecalmicrobiotatransplantationinpatientswithparkinsonsdiseaseclinicaltrialresultsfromarandomizedplacebocontrolleddesign |